Sarepta Therapeutics ($SRPT) has received full FDA approval for its gene therapy for ambulatory patients with Duchenne muscular dystrophy (DMD) and accelerated approval for non-ambulatory patients, as detailed in Elevidy's FDA label. This approval is expected to drive significant revenue growth for the company in the coming quarters. BMO Capital has set a conservative target price of $200 for Sarepta's stock, citing no meaningful competition in the near future. Despite this positive outlook, some investors are skeptical, noting disappointment within the DMD community regarding the therapy and Peter Mark's decision, as well as concerns about the empty capsid ratio in AAV technologies.
Great account to follow if interested in biotech investing 👇 https://t.co/7tvY0mlhBe
Excellent tweet to read. And I may add the empty capsid ratio is the one of the main reasons why I stopped investing in AAV technologies ( $SRPT was a too good, too easy oppty to miss). Not sure this critical problem can ever be solved in the near future Rather investing in… https://t.co/aWq3wqgYqZ
Excellent tweet to read. And I may add the empty capsid ratio is the one of the main reasons why I stopped investing in AAV technologies ( $SRPT was a too good, too easy oppty to miss). Not sure this problem can be solved. Rather investing in other modalities IMHO. https://t.co/aWq3wqgYqZ
Read. $SRPT https://t.co/xy3149CzG7
Quickly wanted to expand on my new $SRPT thesis, both from a clinical and investment perspective. First, the clinical piece: I *love* medical innovation, especially for kids with rare diseases. I cried when $VRTX press released the initial data for the CF triple. I had…
$SRPT Excellent post from Joe who knows Sarepta than anyone else on here. I’m long Sarepta from days it was trading just over 10 bucks Back than plenty of risks associated with fda adcom, approval decision and or label restrictions All in hindsight and strong labeling now will… https://t.co/LrQ4t1FxkC
$SRPT no meaningful competition for quite some long time $200 still a low conservative target by BMO Capital. Quarterly earnings going to show tremendous growth next several quarters $SLDB I have a lotto position only. Hasn’t proven anything yet over last so many years. Until… https://t.co/U6MUjgcLmj
I‘ve exited our $SRPT long position. And I actually think it‘s a great short. Here‘s some of my thinking (let me know where I‘m wrong): I was surprised to learn that the majority of the DMD community is disappointed with both Sarepta‘s Gene Therapy and Peter Mark‘s decision.… https://t.co/BeIEP9lQFf
$SRPT will be that high growth revenue story from here on after receiving full approval for ambulatory patients and getting accelerated approval for non ambulatory patients. See Elevidy's FDA label. No competition for years to come